Vanguard Global Advisers
STOK icon

Vanguard Global Advisers’s Stoke Therapeutics STOK Stock Holding History

Vanguard Global Advisers’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$872K Hold
26,639
– – ﹤0.01% 1822
2026
Q1 		$867K Buy
+26,639
New +$874K ﹤0.01% 1734

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Global Advisers's STOK Position: Q2 2026 in Review

Vanguard Global Advisers held its Stoke Therapeutics (STOK) position steady in Q2 2026 at 26,639 shares worth $872K. The position accounts for ﹤0.01% of the portfolio, ranked #1822.

Vanguard Global Advisers first reported a position in STOK in Q1 2026 and has held it in 2 quarters since. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Vanguard Global Advisers held 26,639 shares of Stoke Therapeutics worth $872K as of Q2 2026.
  • Vanguard Global Advisers left its Stoke Therapeutics share count unchanged in Q2 2026.
  • Stoke Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1822 holding.
  • Vanguard Global Advisers first reported a position in Stoke Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.